Pulls together national guidelines for multiple sclerosis care and services in England, Scotland, Wales and Northern Ireland. Includes details about the revised NICE clinical guidelines, multiple sclerosis in adults: management, published in June 2022.

MS is most often diagnosed between the ages of 20-40, when many people may be thinking of starting, or extending, their family. Having MS can raise questions to consider, these may include: whether MS will affect your fertility; what the risk of your children developing MS is; what effect medications taken before and during pregnancy may have; and for women, what effect the pregnancy itself may have on your MS.

Tyruko (natalizumab) is a disease modifying drug treatment for relapsing remitting MS. It is a biosimilar alternative to Tysabri, taken as an intravenous infusion every four weeks.

Lemtrada (alemtuzumab) is a disease modifying drug treatment for relapsing remitting MS. You take Lemtrada as an intravenous infusion (drip) in two treatment courses, twelve months apart.

Gilenya (fingolimod) is a disease modifying drug treatment for relapsing remitting MS. You take Gilenya as a pill once a day.

Ponvory (ponesimod) is a disease modifying drug treatment for relapsing remitting MS. You take Ponvory as a pill once a day.

Tecfidera (dimethyl fumarate) is a disease modifying drug treatment for relapsing remitting MS. You take Tecfidera as a pill twice a day.

Vumerity (diroximel fumarate) is a disease modifying drug licenced for relapsing remitting multiple sclerosis (MS).  It is taken as two tablets, twice a day.

Ocrevus (ocrelizumab) is a disease modifying drug treatment for relapsing remitting and early primary progressive MS. It is taken as an infusion into a vein or an injection under the skin every six months.